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Abdominal aortic aneurysm (AAA), an inflammatory disease, involves leukocyte recruitment, immune respons-
es, inflammatory cytokine production, vascular remodeling, neovascularization, and vascular cell apoptosis, 
all of which contribute to aortic dilatation. This study demonstrates that mast cells, key participants in human 
allergic immunity, participate in AAA pathogenesis in mice. Mast cells were found to accumulate in murine 
AAA lesions. Mast cell–deficient KitW-sh/KitW-sh mice failed to develop AAA elicited by elastase perfusion or peri-
aortic chemical injury. KitW-sh/KitW-sh mice had reduced aortic expansion and internal elastic lamina degradation; 
decreased numbers of macrophages, CD3+ T lymphocytes, SMCs, apoptotic cells, and CD31+ microvessels; and 
decreased levels of aortic tissue IL-6 and IFN-γ. Activation of mast cells in WT mice via C48/80 injection resulted 
in enhanced AAA growth while mast cell stabilization with disodium cromoglycate diminished AAA forma-
tion. Mechanistic studies demonstrated that mast cells participated in angiogenesis, aortic SMC apoptosis, and 
matrix-degrading protease expression. Reconstitution of KitW-sh/KitW-sh mice with bone marrow–derived mast 
cells from WT or TNF-α–/– mice, but not from IL-6–/– or IFN-γ–/– mice, caused susceptibility to AAA formation to 
be regained. These results demonstrate that mast cells participate in AAA pathogenesis in mice by releasing pro-
inflammatory cytokines IL-6 and IFN-γ, which may induce aortic SMC apoptosis, matrix-degrading protease 
expression, and vascular wall remodeling, important hallmarks of arterial aneurysms.
*OUSPEVDUJPO
Abdominal aortic aneurysm (AAA), a common aortic disease in 
the elderly, with an unknown pathogenesis, is characterized by 
extensive tissue remodeling, neovascularization, inflammatory cell 
infiltration, and vascular cell apoptosis, all of which contribute 
to aortic dilatation, the sine qua non of the disease (1). Leuko-
cyte recruitment is a key feature of human AAA. After infiltration, 
the neutrophils, macrophages, and lymphocytes in human AAA 
lesions produce a spectrum of proinflammatory cytokines and 
matrix-degrading proteases that promote formation of AAA (1). 
Selective depletion of neutrophils (2), lymphocytes (3), matrix-
degrading proteases (4, 5), or proinflammatory cytokines (6) 
impairs experimental AAA formation.
Mast cells are another inflammatory cell type recently identified 
in human aortic lesions, including those of atherosclerosis and AAA 
(7, 8). Classically, mast cells have been described as essential effector 
cells of immediate hypersensitivity and chronic allergic reactions that 
contribute to asthma, atopic dermatitis, and other allergic diseases 
(9). Despite the lack of direct evidence of mast cell participation in 
either atherosclerosis or AAA, enhanced accumulation of mast cells 
during human atherogenesis and AAA formation suggests that mast 
cells play a role in the pathogenesis of these vascular diseases. For 
example, active chymase, a unique mast cell protease important in 
the formation of angiotensin II and activation of MMP (10, 11), has 
been found at increased levels in extracts of human AAA lesions. Chy-
mase-positive mast cells were detected in the media and adventitia 
in human AAA (8). Pharmacological inhibition of chymase activity 
reduces AAA progression in hamsters (12). In addition to a unique 
set of proteases, mast cells also release proinflammatory cytokines 
(IFN-γ, TNF-α, and IL-4, -5, -6, and -13) and chemokines (monocyte 
chemoattractant protein–1 [MCP-1], IL-8, RANTES), all of which 
may directly or indirectly participate in AAA formation. Stabiliza-
tion of mast cells with disodium cromoglycate (DSCG) blocked the 
increase of plasma IL-6 in ApoE–/– mice (13). Many in vitro and in 
vivo studies have also demonstrated that IL-6 plays a role in lympho-
cyte activation and that IFN-γ stimulates lymphocytes, macrophages, 
ECs, and fibroblasts. In addition to activating T cells and B cells, IL-6 
is required for fibroblast and EC MCP-1 expression, macrophage and 
leukocyte recruitment, MMP expression, angiogenesis, angiotensin 
II–mediated macrophage oxidized LDL uptake, and angiotensin 
II–mediated reactive oxygen species production and endothelial dys-
function, all of which are important to AAA pathogenesis (7). Mice 
lacking IFN-γ are resistant to AAA (3). Injection of IFN-γ into CD4+ 
T cell–depleted mice, which are resistant to aneurysm induction, can 
partially reconstitute aneurysms in CD4–/– mice (3).
However, other inflammatory cell types in AAA lesions, such as 
macrophages, neutrophils, and lymphocytes, also produce potent 
extracellular matrix proteases as well as the aforementioned mast 
Nonstandard abbreviations used: AAA, abdominal aortic aneurysm; BMMC, bone 
marrow–derived mast cell; DSCG, disodium cromoglycate; IEL, internal elastic lamina; 
MCP-1, monocyte chemoattractant protein–1; PDTC, pyrrolidine dithiocarbamate.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 117:3359–3368 (2007). doi:10.1172/JCI31311.
Downloaded on August 12, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/31311
SFTFBSDIBSUJDMF
 The Journal of Clinical Investigation   http://www.jci.org   Volume 117   Number 11   November 2007
cell mediators. For example, macrophages are a major source of 
the vascular wall destructive cysteine proteases (14), MMP (4, 5), 
and the proinflammatory cytokines TNF-α, IL-1β, and IFN-γ (3, 
15), implicated in the development of human and murine AAA. 
Lymphocytes produce Th1 and Th2 cytokines in human arterial 
diseases (3, 15). Our recent studies demonstrated that CD4+ T 
cells, the major lymphocytes in human AAA lesions (3), produce 
MMP-9 and the cysteine proteases cathepsins S, K, and L (16), all 
of which are essential to vasculature remodeling (4, 14).
In this study, we used an aorta elastase perfusion–initiated 
mouse AAA model to determine whether mast cells modulate AAA 
formation. Reconstitution of mast cells from different cytokine-
deficient mice into mast cell–deficient mice identified mast cell 
mediators essential to AAA. Finally, we determined whether we 
can regulate mouse AAA formation by activating or stabilizing 
mast cell activities in vivo.
3FTVMUT
Mast cell accumulation and AAA formation. Biochemical observations 
revealed high numbers of chymase- and tryptase-positive mast cells 
in human AAA lesions and suggested an association of mast cell 
accumulation and AAA progression (8). To test this hypothesis, we 
used an established elastase perfusion model to produce AAA in 
mice (2, 4). In this model, the infrarenal aorta is locally exposed to 
pancreatic elastase, and aortic expansion forms over a period of 2 
weeks as defined by an increase of aortic diameter by 100% greater 
than that before perfusion (4). Consistently, all mice developed 
AAA 14 days after elastase perfusion (Figure 1A). While normal 
aortas contained few if any mast cells (Figure 1, B and E), a sig-
nificant increase of mast cell content appeared in the adventitia 7 
days after perfusion (Figure 1, C and E) with further increase at 14 
days after perfusion (Figure 1, D and E). Murine mast cells appear 
predominantly in the adventitia (Figure 1, C and D). These obser-
vations indicate that mast cells populate AAA induced by elastase 
perfusion and provide an opportunity to determine experimen-
tally whether AAA formation requires mast cells.
Reduced AAA in mast cell–deficient mice. Accumulation of mast cells 
in AAA lesions suggests a participation of these cells in this disease. 
To test this hypothesis, we studied mast cell–deficient KitW-sh/KitW-sh 
mice in the elastase perfusion–induced AAA model. KitW-sh/KitW-sh 
mice contain a de novo inversion mutation consisting of a break 
point at the upstream regulatory region of the c-kit receptor gene 
that results in reduced Kit receptor expression and defective mast 
cell maturation and survival (17). However, this mutation does 
not affect the number or function of blood leukocytes, includ-
ing lymphocytes (18). Elastase activities of bone marrow–derived 
neutrophils (6,185 ± 94 versus 6,195 ± 26, OD515nm; P = 0.92) and 
blood monocytes (5,980 ± 167 versus 6,274 ± 62, OD515nm; P = 0.18) 
showed no significant difference between WT mice and KitW-sh/
KitW-sh mice. At baseline, histological analysis did not reveal any 
aortic wall elastin degradation, loss of medial SMCs, medial SMC 
apoptosis, or infiltration of macrophages and T cells in aortas 
from either WT or KitW-sh/KitW-sh mice before the elastase perfusion 
(data not shown). However, KitW-sh/KitW-sh mice were protected from 
AAA formation during 56 days following elastase perfusion. After 
perfusion expansion (day 0), the abdominal aortas of KitW-sh/KitW-sh 
mice showed no further expansion on days 7, 14, and 56, whereas 
all WT control mice had an average of more than 110% and approx-
imately 170% aortic expansion 14 and 56 days after perfusion, 
respectively (Figure 2A). Importantly, while the lumen diameters 
of both WT and KitW-sh/KitW-sh mice increased at day 0 by nearly 30% 
due to elastase perfusion, the lumen diameters of KitW-sh/KitW-sh 
mice decreased continuously to those of preperfusion at day 56 
after perfusion. In contrast, although there was a decrease on 
day 7, lumen diameters of WT mice increased consistently over 
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Therefore, the AAA protection in KitW-sh/KitW-sh mice at day 14 
was largely due to attenuation of adventitial thickening, where-
as AAA protection in KitW-sh/KitW-sh mice at 56 days was the result 
of a combination of attenuation of both luminal expansion and 
adventitial thickening. Histological analysis of KitW-sh/KitW-sh mice 
showed better preservation of the internal elastic laminae (IELs) 
(Figure 2C), consistent with higher medial SMC content on day 
14, as determined by semiquantitative grading (Figure 2D). There-
fore, reduced levels of medial SMCs in WT mice may result from 
enhanced IEL fragmentation and an increase in medial SMC death. 
Although most mast cells reside in the adventitia, clusters of mast 
cells exist in the media where elastin degradation and SMC apop-
tosis occur. Immunostaining of serial sections with mouse MCP-4 
(mMCP-4) (mast cells) (19) and α-actin (SMCs) demonstrated 
numerous mast cells but fewer SMCs in the media (Figure 2E), 
suggesting a role of mast cells in medial SMC apoptosis. Further, 
activated mast cells in the adventitia may also release granular con-
tents capable of acting on cells at a distance, such as those in the 
media. Compared with KitW-sh/KitW-sh mice, WT mice showed over-
all more apoptotic cells on days 7 and 14 (∼4-fold) (Figure 2F). 
By staining adjacent sections for both SMCs (α-actin) (Figure 2G) 
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of cell death to the loss of medial SMCs. Media poor in α-actin had 
abundant TUNEL staining. Significantly reduced levels of macro-
phages (Figure 2I) and CD3+ T cells (Figure 2J) in elastase-perfused 
KitW-sh/KitW-sh mice confirmed decreased inflammation.
Neovascularization plays an essential role in AAA formation, and 
its presence associates with AAA lesion rupture (20). To determine 
whether mast cells modulate neovascularization, we stained tissue 
sections with an anti-CD31 antibody and found a reduced content 
of adventitial CD31+ microvessels in KitW-sh/KitW-sh mice both 7 and 
14 days after elastase infusion (Figure 2K). Immunostaining of 
AAA serial sections from WT mice with mMCP-4 and CD31 anti-
bodies demonstrated the presence of both microvessels and mast 
cells in the adventitia (Figure 2L), indicating a possible interaction 
between mast cells and ECs.
Observations from the KitW-sh/KitW-sh mice show that mast cells 
regulate AAA formation and suggest that they do so by modulating 
directly or indirectly the level of cellular inflammation, angiogen-
esis, and SMC apoptosis in aortic wall. However, the present data do 
not exclude the possibility that the reduced inflammation observed 
resulted from decreased AAA formation rather than the converse.
Mast cells promote periaortic CaCl2-induced AAA formation. To further 
test the hypothesis of mast cell participation in AAA pathogenesis, 
we induced AAA formation in WT and KitW-sh/KitW-sh mice using a 
second model of experimental AAA (5). Six weeks after periaortic 
CaCl2 injury, aortic diameter in WT mice increased more than 70%. 
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aortic diameter (Figure 3A) and preservation of the IEL (Figure 3B). 
Under these experimental conditions, no lumenal changes were 
noticed in WT mice 6 weeks after injury and absence of mast 
cells had no effect on lumen diameters. Our data presented in 
Figure 3, A and B, indicate that the prevention of AAA formation 
in KitW-sh/KitW-sh mice is independent of the animal models used.
Mast cell IL-6 and IFN-γ contribute to AAA formation. In KitW-sh/KitW-sh 
mice, protection from AAA formation may result either from 
altered c-kit signaling caused by the inversion mutation of the 
c-kit receptor gene or the absence of mast cells. To differentiate 
these possibilities, we introduced bone marrow–derived mast 
cells (BMMCs) from WT mice and mice deficient in mast cell 
cytokines IL-6, IFN-γ, and TNF-α into the tail veins of KitW-sh/KitW-sh 
mice using an established protocol (18, 19, 21, 22), followed by 
elastase perfusion to induce AAA formation. Reconstitution 
with WT BMMCs largely restored AAA formation and inflamma-
tory cell (macrophages) infiltration in KitW-sh/KitW-sh mice 14 days 
after elastase perfusion (Figure 4, A and B), confirming that the 
absence of mast cells, rather than altered c-kit signaling, protects 
KitW-sh/KitW-sh mice from AAA formation. Despite TNF-α’s role in 
mediating some forms of mast cell–associated inflammation (23), 
KitW-sh/KitW-sh mice reconstituted with TNF-α–deficient BMMCs 
developed AAA and enhanced macrophage accumulation similar 
to those achieved with WT BMMCs. In contrast, BMMCs from 
IL-6– or IFN-γ–deficient mice did not have these effects (Figure 4, 
A and B). Failed restoration of AAA in KitW-sh/KitW-sh mice reconsti-
tuted with IL-6– and IFN-γ–deficient BMMCs did not result from 
altered maturation of IL-6– or IFN-γ–deficient BMMCs. Granular 
morphology, tryptase production, and cell-surface expression of 
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those of WT BMMCs (19). Further, immunostaining with anti-
bodies against mouse chymase mMCP-4 demonstrated that the 
accumulation of IL-6– or IFN-γ–deficient mast cells that appeared 
in reconstituted KitW-sh/KitW-sh mouse abdominal aortas 14 days 
after perfusion (19.3 ± 7.4 and 24.5 ± 3.7 mast cells/mm2, respec-
tively) did not differ significantly from that in abdominal aortas of 
WT or TNF-α–deficient BMMC-reconstituted KitW-sh/KitW-sh mice 
(29.7 ± 6.8 and 20.2 ± 4.9 mast cells/mm2, respectively), indicating 
similar recruitment of the IL-6– and IFN-γ–deficient mast cells to 
the abdominal aortas following elastase perfusion. Therefore, mast 
cell–derived IL-6 and IFN-γ may play key roles in aortic remodel-
ing and expansion. In agreement with this hypothesis, aortas from 
KitW-sh/KitW-sh mice and those reconstituted with IFN-γ– and IL-6– 
deficient BMMCs had significantly fewer IFN-γ–positive areas 
than those in aortic lesions from KitW-sh/KitW-sh mice reconstituted 
with WT or TNF-α–deficient BMMCs (Figure 4, C and D). The 
AAA tissue extract ELISA detected significant reduction of IL-6 in 
KitW-sh/KitW-sh mice relative to WT mice (Figure 4E). Therefore, from 
these experiments, we conclude that mast cell–derived IL-6 and 
IFN-γ play key roles in aortic remodeling and expansion.
Control of AAA by regulating mast cell activation. Activation of mast 
cells and the subsequent release of their granular constituents is a 
major mechanism whereby mast cells participate in pathobiological 
processes (24). Mast cells likely affect AAA pathogenesis by releas-
ing IL-6, IFN-γ (Figure 4, A–E), and possibly other unmeasured 
molecules. Therefore, blocking IL-6 and IFN-γ release might con-
trol AAA formation, a hypothesis tested in atherosclerotic apoE-
deficient mice (13). To determine whether regulation of mast cell 
activation controls AAA formation, we injected compound 48/80 
(C48/80, 4 mg/kg/d), a mast cell degranulation agent, or DSCG 
(25 mg/kg/d), a mast cell stabilizer, i.p. during AAA formation. In 
WT mice, mast cell activation induced by C48/80 increased aortic 
expansion by 40% (Figure 4F). In contrast, the mast cell stabilizer 
DSCG reduced aortic expansion by 40%, suggesting that reduced 
mast cell degranulation limits AAA development. Further, increased 
AAA in C48/80-treated mice and decreased AAA in DSCG-treated 
mice corresponded with changes in IEL fragmentation (Figure 4G), 
suggesting that mast cells regulate the activities of aortic elastases. 
Importantly, increased lesion sizes in C48/80-treated mice accom-
panied enhanced lesion macrophage contents (Figure 4B) but did 
not alter lesion mast cell accumulation as detected by mMCP-4 
immunostaining (Figure 4H), suggesting that C48/80 promotes 
mast cell activation or degranulation and thereby augments the 
release of mast cell mediators. Immunohistological analysis and 
ELISA of AAA tissue extracts from C48/80-treated mice revealed 
significantly higher levels of both IFN-γ (Figure 4, C and D) and IL-6 
(Figure 4E), which could be the result of mast cell activation/degran-
ulation by C48/80. In contrast, impaired AAA lesions in DSCG-
treated mice also showed reduced mast cell numbers (Figure 4H), 
macrophage contents (Figure 4B), and lesional IFN-γ (Figure 4, 
C and D) and IL-6 (Figure 4E) levels, suggesting DSCG affects 
AAA beyond mast cell stabilization, possibly via an antiinflamma-
tory effect (25). Alternatively, altered lesion macrophage contents 
and IFN-γ and IL-6 levels could also be secondary to correspond-
ing changes of AAA lesion formation in C48/80- or DSCG-treated 
mice. Nevertheless, our data demonstrate an impact of C48/80 and 
DSCG in AAA growth and reveal a potential novel target for AAA 
prevention and management in humans.
Expression of elastinolytic cathepsins and MMPs in mouse AAA. Elas-
tases play essential roles in arterial wall remodeling, including 
atherosclerosis and AAA. Deficiencies in elastinolytic cathepsins 
S (26), K (27), and L (16) reduce atherogenesis in mice. Mice defi-
cient in cathepsins C (28) or S (unpublished data) and MMP-9 or 
MMP-2 (4, 5) also develop significantly less AAA in experimental 
models. Mast cells release a unique set of proteases, i.e., tryptase 
and chymase, that may participate in AAA directly or indirectly 
by activating MMP (11). Our recent in vitro study demonstrates 
that mast cells induce elastinolytic cathepsin expression in both 
aortic SMCs and ECs (19). Labeling the cysteine protease active 
site with [125I]JPM (29) (Figure 5, A and B) and determining MMP 
activity by gelatin zymography (Figure 5, A and C) (30) revealed 
much lower cathepsin and MMP activities in aortic extracts from 
KitW-sh/KitW-sh mice than in WT mice 14 days after elastase 
perfusion. Importantly, the activities of cathepsin and MMP in 
'JHVSF
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the aortas of KitW-sh/KitW-sh mice increased following reconstitution 
with BMMCs from WT or TNF-α–deficient mice but not those 
from IL-6– or IFN-γ–deficient mice (Figure 5, B and C), suggesting 
that mast cell–derived IL-6 and IFN-γ stimulate matrix-degrading 
protease IEL degradation (Figure 4, F and G). These observations 
agree with prior in vitro studies (19). BMMCs from IL-6- or IFN-γ– 
deficient mice produce less than 5% IL-6 or IFN-γ of those from WT 
mice. In contrast, BMMCs from TNF-α–deficient mice release 50% 
IL-6 and 30% IFN-γ of those from WT mice and thus may suffice 
to induce vascular cell protease expression in vitro (19) and in vivo 
(Figure 5, B and C). Activities of both cathepsin (e.g., cathepsin B) 
and MMP (e.g., MMP-2) increased in aortic extracts from C48/80-
treated mice but decreased to the levels found in KitW-sh/KitW-sh 
mice following the stabilization of mast cells with DSCG (Figure 5, 
A–C) when both assays contained an equal amount of proteins 
(Figure 5A). In situ elastin zymography optimized for cysteine 
proteases (pH 5.5 with both EDTA and dithiothreitol) supported 
these observations. While negligible elastinolytic activities (green 
fluorescence in the adventitia) were detected in normal aorta, 
saline-treated aorta, and heat-inactivated elastase–treated aorta, 
AAA lesions in WT mice showed much higher elastinolytic activity 
than did those from KitW-sh/KitW-sh mice, as indicated by the differ-
ences in percentage area of adventitia fluorescence in Figure 5D. 
Media green fluorescence may come from both increased elastase 
activity in AAA lesions and intact elastin filament autofluores-
cence, which also appeared in normal aorta and in experiments 
in which elastin substrate was not utilized (Figure 5D). The non-
selective cathepsin inhibitor E64d (20 μM) greatly inhibited such 
activity in parallel sections. Increased AAA expansion (Figure 4F) 
and IEL fragmentation (Figure 4G) in mice treated with the mast 
cell activator C48/80 accompanied enhanced in situ activity of 
cathepsin elastase. Likewise, impaired AAA and reduced IEL 
degradation in DSCG-treated mice (Figure 4, F and G) may have 
resulted, at least in part, from a reduction in elastinolytic cathep-
sin activity (Figure 5D). Omission of fluorogenic elastin substrate 
was utilized for the control (Figure 5D).
Role of mast cells in neovascularization and aortic SMC apoptosis. 
Angiogenesis and apoptosis, like elastinolysis, are common in 
human AAA (20). Inhibition of angiogenesis or apoptosis reduces 
AAA formation in rodents (31, 32). In KitW-sh/KitW-sh mice, decreases 
in the number of microvessels (Figure 2K) and total apoptotic 
cells (Figure 2F) suggest that mast cells participate in these patho-
logic events. After incubating mouse aortic rings in Matrigel with 
degranulated mast cell supernatant from WT mice (Figure 6, 
B and C) but not after incubation with culture medium alone 
(Figure 6, A and C), microvessel sprouting, similar to that seen in 
the aortic rings treated with IL-6–, IFN-γ–, and TNF-α–deficient 
mast cell supernatant (data not shown), occurred at substantial 
levels, suggesting that additional factors from mast cells con-
tributed to microvessel growth in AAA. Immunostaining a cross 
section of the Matrigel with mouse CD31 antibody revealed well-
formed microvessels derived from the aorta after stimulation with 
medium conditioned by mast cell degranulation (Figure 6D).
α-Actin staining of SMCs of AAA lesions in WT mice showed 
areas negative for α-actin (Figure 2G) but rich in apoptotic cells 
(Figure 2H) in contrast to reduced apoptotic cells in lesions of 
KitW-sh/KitW-sh mice (Figure 2F), consistent with a role of mast cells 
in aortic SMC apoptosis (33). To identify mast cell–derived media-
tors important for SMC apoptosis, we used pyrrolidine dithiocar-
bamate (PDTC) with or without supernatant from degranulated 
BMMCs to induce apoptosis of mouse aortic SMCs. TUNEL-
positive cells appeared within hours. However, supernatant from 
degranulated BMMCs from WT and TNF-α–deficient mice but not 
that from IL-6– and IFN-γ–deficient mice enhanced SMC apopto-
sis (Figure 6, E and F), supporting a role of mast cell–derived IL-6 
and IFN-γ in aortic SMC apoptosis.
%JTDVTTJPO
Although mast cells have been identified in human AAA lesions, evi-
dence for a direct participation of mast cells in this vascular disease is 
lacking. The availability of mast cell–deficient mice and established 
mouse AAA models made it possible to determine whether these 
cells are essential mediators of AAA and not merely a hallmark.
This study used a BMMC reconstitution technique to determine 
whether mast cell–derived IL-6, IFN-γ, and TNF-α play a role in 
AAA formation (Figure 4A). TNF-α is expressed in macrophages 
and lymphocytes both in the atherosclerotic (34) and AAA (35) 
lesions. In ApoE–/– mice with diet-induced atherosclerosis, a lack 
of TNF-α reduces atherosclerosis (36). In this model, TNF-α plays 
a proatherogenic role by upregulating expression of the vascular 
adhesion molecules ICAM-1 and VCAM-1 and the chemokine 
MCP-1 in the vascular wall and by inducing expression of scaven-
ger receptor class A and uptake of oxidized LDLs in macrophages. 
Although it remains to be determined whether TNF-α plays a simi-
lar role to that in atherosclerosis, both serum (37) and aneurysmal 
tissues (35) from AAA patients have increased TNF-α levels. How-
ever, our data with TNF-α–/– mast cells did not support a direct 
role of mast cell–derived TNF-α in AAA. This does not exclude the 
possibility that TNF-α plays a role in AAA formation; rather, it is 
possible that TNF-α produced from other cells may compensate 
for its absence from mast cells.
AAA formation requires mast cell IFN-γ and IL-6 but not TNF-α. 
Reconstitution of mast cell–deficient KitW-sh/KitW-sh mice with 
IFN-γ–/– or IL-6–/– BMMCs did not restore the AAA phenotype 
(Figure 4A). These observations agree with the findings in IFN-γ–/– 
mice (3), which are protected from CaCl2-induced AAA. Both this 
study (3) and others using a histocompatibility-mismatched aortic 
transplantation model in IFN-γ receptor–deficient recipient mice 
(6) demonstrated that Th2-slanted immune responses promote 
AAA formation. Indeed, mast cells from IL-6–/– and IFN-γ–/– mice 
produce negligible IFN-γ and IL-6, suggesting cooperative regula-
tion of these 2 cytokines (19). HeLa cells and monocytes exhibit 
IFN-γ–regulated expression of IL-6 (38, 39). Enhanced IL-6 and 
IFN-γ, which may come in part from mast cells, were detected in 
cultured explants of human AAA lesions and in serum of AAA 
patients (15, 40). AAA sections or tissue extracts from WT mice 
contained much higher levels of both IFN-γ and IL-6 than those 
from KitW-sh/KitW-sh mice (Figure 4, C–E). In addition to their possible 
roles in activating macrophages and inducing MMP and cysteine 
protease expression (41), which are also critical to AAA formation 
(4, 5), IL-6 and IFN-γ appeared to regulate the formation of AAA 
by modulating lesional SMC apoptosis (Figure 6, E and F). Our 
observations from in vitro cell-based assay and the murine AAA 
model not only demonstrate that mast cell–derived IL-6 and IFN-γ 
are essential to AAA but also suggest that other sources of IL-6 and 
IFN-γ, e.g., inflammatory cells such as T cells (3) and macrophages 
(42), do not compensate for their absence in mast cells. Such cell 
type–dependent functional specificity is not unique to IL-6 and 
IFN-γ, as similar activity has been reported for other cytokines. For 
example, mast cell TNF-α is required for recruiting neutrophils to 
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infected tissue compartments (43), macrophage and neutrophil 
TNF-α are required for resistance to intracellular Listeria infection, 
and T cell TNF-α is required for protection from high bacterial 
loads (44). Thus, while it may seem intuitive that, because cytokines 
are made by many cell types, the absence of their production by one 
cell type would be compensated for by their production by another 
cell type, when tested in experimental models, this compensation 
does not always prove to be true, and depending on the end point 
measured, a single cellular source of a cytokine can have profound 
influence over modulating that end point.
Our in vitro experiments demonstrate that mast cell–derived 
IL-6 and IFN-γ are required for apoptosis but not neovascular-
ization. Insignificant differences in the microvessel growth from 
the aortic ring Matrigel assay between WT and IL-6–, IFN-γ–, and 
TNF-α–deficient BMMCs suggest that mast cell mediators other 
than IL-6, IFN-γ, and TNF-α modulate neovascularization in this 
assay even though IFN-γ, IL-6, and TNF-α have been implicated in 
angiogenesis. In fact, mast cell–derived bFGF, angiopoietin-1, chy-
mase/tryptase, and a number of other proinflammatory cytokines 
and chemokines (45) have been implicated in angiogenesis. These 
mast cell mediators may have obscured the effect of mast cell IL-6, 
IFN-γ, and TNF-α in our in vitro assays (Figure 6, A–C).
Pharmacologic regulation of mast cell activation and degranula-
tion directly controlled AAA formation in mice (Figure 4, F and G). 
These data not only strengthen the hypothesis that mast cells are 
essential mediators of AAA pathogenesis but also suggest that 
treatments blocking mast cell degranulation may prevent or delay 
AAA progression in humans. Compound 48/80 has been widely 
used to degranulate mast cells in live animals (46). Although the 
detailed mechanisms of how C48/80 activates mast cells need to 
be investigated further, recent observations suggest that C48/80 
acts on mast cells via activation of phospholipase D (47) and Gαi3 
G protein subunits (48) to trigger the release of histamine as well as 
other granule components including cathepsins and MMP-activat-
ing chymases or cytokines, which may influence neighboring vascu-
lar cells. This hypothesis is supported by the findings of increased 
cysteine protease and MMP activities, elevation of AAA tissue IFN-γ 
and IL-6, and enhanced medial elastin degradation in aortic tissues 
isolated from C48/80-treated mice (Figure 4). In contrast, DSCG is 
a drug widely used in the treatment of asthmatic patients. Obser-
vations from in vitro tests and animal models show that the effect 
of DSCG is related to mast cell stabilization. Importantly, this 
compound reduces mouse AAA by 40% (Figure 4). Impaired AAA 
in DSCG-treated mice is likely due to reduced release of mast cell 
granule contents. This hypothesis is consistent with reduced AAA 
lesion cysteine protease and MMP activities and IFN-γ and IL-6 lev-
els found in DSCG-treated mice (Figures 4 and 5).
While this study provides evidence that mast cells regulate AAA 
formation, it also leaves several important questions unanswered. 
First, depletion of neutrophils in mice impairs elastase perfusion–
induced AAA (2), and mice lacking T lymphocytes have protec-
tion from CaCl2-induced AAA (3). Determination of whether lack 
of mast cells in the current study affected the function of either 
neutrophils or T lymphocytes will require further investigation. 
Although we did not find significant differences of elastase activ-
ity of neutrophils from WT and KitW-sh/KitW-sh mice, unrecognized 
interactions between these cell types may exist. Second, it remains 
unknown what mediated the increased number of mast cells in 
the injured aortas following elastase perfusion. Five weeks after 
reconstitution, we detected few if any mast cells in the aortas. In 
contrast, elastase perfusion enhanced mast cell numbers in the 
aortas. One possible explanation is that elastase perfusion induces 
aortic wall SMC expression of chemokines MCP-1 and RANTES 
(49), which may attract mast cells (50). Further, elastase perfusion 
may generate elastin degradation products that signal fibroblast, 
monocyte, and macrophage chemotaxis (51). Delineation of the 
exact mechanism will require further investigation. Third, mast 
cell–mediated neovascularization and SMC apoptosis remain 
poorly understood. Although our data suggest that SMC apoptosis 
involves mast cell–derived IFN-γ and IL-6, whether these cytokines 
regulate SMC apoptosis directly or indirectly remains unknown. 
Our prior study demonstrated that mast cell IFN-γ and IL-6 aug-
ment SMC and EC expression of cysteine proteases (19), which 
participate in cell apoptosis (52). IFN-γ and IL-6 from mast cells 
may have induced cathepsin expression and further led to SMC 
apoptosis, a hypothesis that has not been tested in the current 
study. Fourth, it remains uncertain whether increased expression 
and activities of cathepsins and MMP in AAA lesions (Figure 5) 
come from mast cells or other vascular cells. Mast cells contain 
large quantities of cathepsins (53) and mast cell chymases that par-
ticipate importantly in MMP activation (11). However, mast cell 
cytokines (e.g., IL-6 and IFN-γ) are known stimulators of cathepsin 
and MMP expression, and our previous study (19) and the current 
study demonstrate concurrently their importance in arterial wall 
remodeling. Therefore, it is possible that mast cells contribute to 
AAA by releasing both proteases and cytokines, a hypothesis that 
requires further investigation.
In summary, data from this study establish that mast cells play 
a role in the development of AAA by affecting matrix-degrading 
protease expression, medial SMC apoptosis, and microvessel growth. 
More importantly, our data suggest a novel and effective therapeutic 
strategy to control human AAA progression by preventing release of 
mast cell products using mast cell–stabilizing compounds.
.FUIPET
AAA production. Eight- to ten-week-old male WT mice (from The Jackson 
Laboratory, C57BL/6 background) and male KitW-sh/KitW-sh mice (C57BL/6 
background) (17, 21) were used for aortic elastase perfusion, as detailed 
elsewhere (4). Aortic diameters were measured before the surgery (day 
–1), immediately following elastase perfusion (day 0), and 7, 14, and 
56 days after perfusion. Abdominal aortas were harvested at each time 
point. Lumen diameters were determined by measuring the lumen perim-
eters of cross sections of frozen aortas.
To produce AAA by periaortic chemical injury, 8-week-old male mice 
were used for aorta CaCl2 injury as described (5). Aortic diameters were 
measured before CaCl2 application and 6 weeks after the injury.
To harvest AAA tissues, after measuring the aortic diameter and collect-
ing the blood, we removed the aortic zone of maximal expansion, either 
directly freezing the tissue for protein extraction or OCT embedding for 
cross section preparation. Immunohistological analysis used 6-μm sec-
tions while in situ elastin zymography used 8-μm cross sections. All mouse 
experiments were performed under a protocol preapproved by the Animal 
Research Committee of Harvard Medical School.
BMMC preparation and reconstitution. WT (C57BL/6), IFN-γ–/– (con-
genic C57BL/6, N10), IL-6–/– (congenic C57BL/6, N11), and TNF-α–/– 
(C57BL/6*129/Sv, N1) mice were obtained from The Jackson Laboratory. 
TNF-α–/– mice were backcrossed to a congenic C57BL/6 background (N10). 
Bone marrow was isolated from these mice for BMMC differentiation for 
5 weeks in the presence of recombinant murine IL-3 (PeproTech) and murine 
stem cell factor (PeproTech) as reported (21). At this time, the cell popula-
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tions consisted of more than 95% mast cells as assessed by the presence of 
metachromatic granules in toluidine blue–stained cells and FACS analy-
sis for the disappearance of progenitor cell marker stem cell antigen-1. To 
reconstitute BMMCs in vivo, the tail veins of 5-week-old male KitW-sh/KitW-sh 
mice were injected with BMMCs (1 × 107 cells/mouse). Mice were perfused 
with elastase to produce AAA 5 weeks after reconstitution.
Mast cell activation and stabilization in vivo. C48/80 activated the mast cells 
in WT mice, and DSCG stabilized the mast cells in WT mice. After mice 
(C57BL/6, male, 10 weeks old) recovered from elastase perfusion surgery 
(day 0), they received the first i.p. injection of C48/80 (Sigma-Aldrich, 
4 mg/kg/d) or DSCG (Sigma-Aldrich, 25 mg/kg/d). Each animal received 
daily injection for the duration of the experiment thereafter (14 days).
Mast cell content measurement. Immunostaining with rabbit anti-mouse 
mMCP-4 antibody (1:150) determined the mast cell number on aortic sec-
tions (19). Antibody specificity was confirmed using WT mouse AAA sec-
tions immunostained with rabbit preimmune serum and KitW-sh/KitW-sh mouse 
aortic sections immunostained with the mMCP-4 antibody at the same anti-
body dilution. The total number of mMCP-4-positive cells on each section 
were counted manually and blindly, and the total area was determined using 
computer-assisted image analysis (Image-Pro Plus; MediaCybernetics).
Immunohistochemistry, ELISA, and lesion characterization. Frozen sections 
(6 μm) were stained for macrophages (Mac-3), T cells (CD3), SMCs (α-actin), 
ECs (CD31), mast cells (mMCP-4), elastin (Verhoeff–van Gieson), and IFN-γ 
as described previously (19, 26). Lesion apoptotic cells were determined 
with the In situ Apoptosis Detection kit according to the manufacturer’s 
instructions (Chemicon International). Elastin degradation and lesion 
SMC content were graded according to the grading keys shown in Figure 2, 
C and D. To determine lesion IL-6 levels, frozen aortas were pulverized for 
protein extraction in a pH 7.5 buffer containing 50 mM NaAc and 1% Tri-
ton X-100. Protein concentration was determined with a BCA kit (Bio-Rad) 
and IL-6 levels measured by ELISA (R&D Systems). All immunostained 
cells were counted or calculated blindly by at least 2 observers.
Cysteine protease active site labeling and gelatin gel in situ zymogram. Pulverized 
aortic tissues were lysed in a pH 5.5 buffer. The cysteine protease activity 
in tissue lysates was determined with [125I]JPM labeling (2 μg protein/lane) 
(29), and the MMP activity was assessed by in-gel gelatinase zymogram assay 
(5 μg protein/lane) as described (30). Equal protein loading (7 μg protein/
lane) was confirmed by SDS-PAGE followed with Coomassie staining.
Mast cell degranulation, aortic ring assay, and SMC apoptosis assay. In vitro–dif-
ferentiated BMMCs were degranulated with mouse anti-DNP IgE mono-
clonal antibody as described previously (54). Degranulation efficiency was 
calculated as follows: (experimental supernatant − control supernatant)/
(experimental supernatant + experimental cell lysates supernatant).
An aortic ring assay was used to test mast cell function in angiogenesis. 
In brief, a 96-well plate was coated with 50 μl of Matrigel (BD Biosciences). 
A 1-mm–long mouse aortic ring was laid on the top of the Matrigel and 
covered with 100 μl of Matrigel. After solidification, 100 μl of RPMI 
(10% FBS) with or without 100 μl of degranulated BMMC supernatant 
was added to each well. After 7–10 days of culture, the aortas were photo-
graphed and the endothelial outgrowth was analyzed using Image-Pro Plus 
software. To confirm a microvessel phenotype of sprouts from the aortic 
ring, a Matrigel containing aortic ring and sprouts was embedded in OCT 
followed by sectioning and immunostaining with CD31.
Mouse aortic SMC apoptosis was induced with 50 μM of PDTC (Sigma-
Aldrich) as previously described with or without degranulated mast cell 
supernatant prepared from the same amount of BMMCs (55). Apoptotic 
SMCs were detected using the in situ cell death detection kit according 
to the manufacturer’s instructions (Roche Applied Science). Data were 
presented as mean ± SE of percentage of apoptotic cells.
In situ elastin zymography. AAA lesion elastinolytic activity was determined 
in 8-μM frozen sections using elastin conjugated with quenched fluorescein 
(DQ elastin; Invitrogen) as a substrate, which requires cleavage by elastino-
lytic enzymes to become fluorescent. In brief, DQ elastin (1 mg/ml in H2O) 
was mixed 1:10 with 1% low-melting agarose (Sigma-Aldrich). This mixture 
(20 μl) was added on top of each section, coverslipped, and gelled at 4°C. 
Following incubation at 37°C (48 hours), fluorescence was examined under 
fluorescent microscopy. Cysteine protease activity was determined using an 
EDTA-containing pH 5.5 buffer (56) with or without E64d (20 μM). Zymo-
graphic images were acquired using identical shutter conditions. The per-
centage of fluorescence intensity of each cross section, excluding the media 
area due to medial elastin filament autofluorescence, was measured using 
computer-assisted image quantification (Image-Pro Plus software).
Neutrophil and monocyte elastase activity assay. Neutrophils from WT and 
KitW-sh/KitW-sh mice were prepared from bone marrow by gradient cen-
trifugation. Bone marrow cells were overlaid on the top of 62.5% Per-
coll (Sigma-Aldrich) followed by centrifugation at 600 g for 30 minutes. 
Purified neutrophils were lysed in a pH 8.5 buffer containing 150 mM 
NaCl, 200 mM Tris HCl, and 1% Triton X-100. Monocytes from WT and 
KitW-sh/KitW-sh mice were isolated from blood by overlaying diluted blood 
(1:1 in PBS) on LSM Lymphocyte Monocyte Separation Medium (LLC; 
MP). Isolated monocytes were lysed in a pH 5.5 buffer containing 50 mM 
NaAc, 1% Triton X-100, and 12 mM dithiothreitol. Equal amounts of 
protein (60 μg) were added to a final volume of 100 μl with 50 μg of 
elastin conjugated with quenched fluorescein (DQ elastin; Invitrogen) 
followed by incubation at 37°C for 24 hours. Elastase activity was deter-
mined by measuring the OD513nm.
Statistics. The statistical significance of data sets from this study was 
examined with a nonparametric Mann-Whitney test. Data from the 
gel densitometry analysis were also analyzed using the nonparametric 
Mann-Whitney test due to the relatively small sample sizes and the non-
Gaussian distribution of the data. P values of less than 0.05 were con-
sidered significant.
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